XML 47 R38.htm IDEA: XBRL DOCUMENT
v3.25.2

Stock-Based Compensation Expense (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract] |
Schedule of Employee Awards and Non-employee Director Award Plan Activity | The Company granted the following awards (in shares):
|  | Three Months Ended March 31, |  |  | Three Months Ended June 30, |  |
|  | 2025 |  |  | 2025 |  |
Employee awards: |  |  |  |  |  |  |
RSUs |  |  | 767,353 |  | (1) |  | 1,695,403 |  | (2)
Market RSUs |  |  | — |  |  |  | 1,715,000 |  | (3)
Performance RSUs |  |  | — |  |  |  | 1,000,000 |  | (4)
Non-employee director RSUs |  |  | — |  |  |  | 443,974 |  | (5)
Total awards issued |  |  | 767,353 |  |  |  | 4,854,377 |  |
_________________________ (1) RSUs had a weighted average grant date fair value of $5.26 per share, of which 263,160 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date and 504,193 RSUs had a vesting period of 25% annually over four years. (2) RSUs had a weighted average grant date fair value of $4.72 per share, of which 1,405,713 RSUs had a vesting period of 25% annually over four years, 204,690 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, 50,000 RSUs vest 100% on July 15, 2027, 30,000 RSUs vest 100% on the second anniversary of the vesting determination date, and 5,000 RSUs will vest 100% on July 15, 2026. (3) 1,715,000 market RSUs had a grant date fair value of $10.84 per share and will vest on July 15, 2028. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. (4) 1,000,000 performance RSUs had a grant date fair value of $3.80 per share and will vest on March 15, 2028. The number of shares delivered on the vesting date, as a percentage of the specified target, shall be determined by the net sales achieved by the Endocrine Business Unit, as reported by the Company for the period from October 1, 2027 to December 31, 2027 as follows: less than $37.5 million=0% target, $37.5 million=25% target, $50.0 million=50% target, $75.0 million=100% target, and $100.0 million or higher=200% target. (5) RSUs had a weighted average grant date fair value of $4.57 per share and vested immediately upon the grant date; however, the underlying shares of common stock will not be delivered until there is a separation of service such as resignation, retirement or death.
Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations | Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue – collaborations and services, R&D and selling, general and administrative expense was as follows (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
RSUs and options |  | $ | 7,357 |  |  | $ | 6,248 |  |  | $ | 12,569 |  |  | $ | 9,947 |
Employee stock purchase plan |  |  | 163 |  |  |  | 180 |  |  |  | 336 |  |  |  | 366 |
Total |  | $ | 7,520 |  |  | $ | 6,428 |  |  | $ | 12,905 |  |  | $ | 10,313 |

X
- Definition Schedule of share based compensation employee stock purchase plan and non employee director stock award plan activity. + References No definition available. + Details
Name: | mnkd_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanAndNonEmployeeDirectorStockAwardPlanActivityTableTextBlock
Namespace Prefix: | mnkd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration